The U.S. Food and Drug Administration approved topical ruxolitinib (Opzelura), the first and only topical formulations of a JAK inhibitor, for the treatment of non-immunocompromised patients with mild-to-moderate atopic dermatitis at least 12 years of age in September 2021. This feature discusses its approval process and its efficacy.
First Topical JAK Inhibitor for Atopic Dermatitis Receives FDA Approval
